Acquisition deal values up to approximately $285 million

Celcuity announces strong Phase 3 VIKTORIA-1 results in the wild-type PIK3CA cohort and plans NDA submission in Q4 2025.

Experimental drug significantly improved wakefulness and reduced excessive daytime sleepiness in narcolepsy type 2

Pfizer und Novo Nordisk liefern sich ein Bieterrennen um Metsera.

Why timing the market isn’t luck. It’s a skill that separates smart trades from missed opportunities.